Skip to main content
Smart Investors Daily
Regeneron Pharmaceuticals, Inc. logo

NYSE · REGN

Regeneron Pharmaceuticals, Inc.

Healthcare · Biotechnology

$945.53

Down-$22.19 (-2.35%)

Updated Nov 20, 2026, 1:17 AM

SID Score

7.4/10

Composite research score

Smart Money

58/100

Neutral

Market cap
77.16B
P/E ratio
16.91
Dividend yield
0.37%
52-week range
$591.52 – $991.73
Volume
705.41K
Avg. volume
1.09M

Price performance · REGN

REGN price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 18, 2026

REGN closed at $945.53 after 20 trading sessions, up 15.44% for the selected period.

Last close
$945.53
Period change
+15.44%
Period low
$805.02
Period high
$973.36
Daily close
View OHLC price history
REGN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 18, 2026$957.25$972.00$943.26$945.53705.41K
Nov 17, 2026$952.56$965.48$946.94$957.76933.41K
Nov 16, 2026$963.32$972.24$947.81$952.40700.86K
Nov 13, 2026$952.47$961.94$942.00$955.471.17M
Nov 12, 2026$972.30$981.55$944.71$951.191.21M
Nov 11, 2026$904.99$961.98$898.29$959.411.23M
Nov 10, 2026$915.34$919.72$905.38$916.06517.08K
Nov 9, 2026$922.35$933.355$901.07$919.96856.76K
Nov 6, 2026$887.22$911.64$887.04$904.351.12M
Nov 5, 2026$938.51$948.11$901.53$902.901.41M
Nov 4, 2026$989.90$991.73$927.42$930.671.4M
Nov 3, 2026$956.28$975.485$953.00$973.361.2M
Nov 2, 2026$927.22$974.00$927.00$961.261.66M
Oct 30, 2026$869.43$935.35$839.08$927.892.87M
Oct 29, 2026$826.14$828.1899$811.63$818.77789.3K
Oct 28, 2026$807.06$821.16$802.20$813.27536.5K
Oct 27, 2026$807.67$816.14$804.05$816.10726.15K
Oct 26, 2026$812.31$817.1699$796.61$807.67423.96K
Oct 23, 2026$819.09$819.09$801.22$805.02527.74K
Oct 22, 2026$809.01$825.52$800.00$819.09852.59K

Latest REGN news

The latest Smart Investors Daily articles mentioning REGN.

REGN research

Overview

Company profile and research snapshot.

Company profile

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$776.80
Implied upside
—
Analysts
25
REGN recent ratings
DateFirmRatingTarget
Nov 17, 2026BarclaysOverweight—
Nov 2, 2026Truist SecuritiesBuy—
Nov 2, 2026RBC CapitalSector Perform—
Nov 2, 2026Morgan StanleyEqual-Weight—
Nov 2, 2026BernsteinMarket Perform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Jul 31, 2026

AbbVie Bought Apogee to Strengthen Its Portfolio. Now It’s Cutting Earnings Guidance.

AbbVie shares took a hit Friday after costs related to the drugmaker’s acquisition of Apogee Therapeutics forced a cut to its full-year profit outlook. Second-quarter revenue jumped 10% to nearly $17 billion, beating the $16.8 billion consensus estimate among analysts polled by FactSet. AbbVie posted adjusted earnings of $3.65 a share, narrowly ahead of Wall Street’s call for $3.60.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.